[X]



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

	with the United States Postal Service				
ate indicated below an	d in an envelope addressed to: Comn	nissioner			
/ h					
Man &	x flener)				
Signature					
Date of Deposit: Alan F. Feeney					
Printed name of persor	n mailing correspondence				
Art Unit:	1631				
Examiner:	BORIN, MICHAEL L.				
Title: ENCAPSULATION OF A WATER SOLUBLE PEPTIDE					
ION DISCLOSUR	E STATEMENT				
-	Alan F. Feeney Printed name of person Art Unit: Examiner: SOLUBLE PEPTID	Alan F. Feeney Printed name of person mailing correspondence Art Unit: 1631 Examiner: BORIN, MICHAEL L.			

AND AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir: This Information Disclosure Statement is submitted: under 37 CFR 1.129(a), or [] (First/Second submission after Final Rejection) [] under 37 CFR 1.97(b), or (Whichever occurs last of the following: within three months of filing national application; within three months of date of entry of the national stage in international application; before the mailing date of first office action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination) [X] under 37 CFR 1.97(c) together with either: [] a Statement under 37 CFR 1.97(e), as checked below, or a \$180.00 fee under 37 CFR 1.17(p), or (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first) [] under 37 CFR 1.97(d) together with: a Statement under 37 CFR 1.97(e), as checked below, and [] [] a Petition under 37 CFR 1.97(d)(2), and [] a \$130.00 petition fee set forth in 37 CFR 1.17(i). (Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee) [] Applicant requests that the attached IDS and cited reference(s) [] be placed in the application filewrapper. (Filed after payment of issue fee)

Some of the listed references were cited in a European Search Report in a counterpart European application or cited

in a communication from a foreign patent office in a counterpart foreign application.

[X]	Enclosed herewith is form PTO/SB/08B (2 pages), with a copy of each reference noted thereon.				
[]	Copies of the reference(s) noted on the enclosed form PTO/SB/08 were previously cited by or submitted to the Patent and Trademark Office in connection with U.S. Application Serial No. [], from which the present application claims benefit under 35 U.S.C. § 120 (37 C.F.R. 1.98(d)).				
Concise	Concise Explanation Requirement (non-English references):				
[]	The "concise explanation" requirement for reference(s) under 37 CFR 1.98(a)(3) is satisfied by:				
	[] the explanation provided on the attached sheet.				
	[] the explanation provided in the Specification.				
	[] submission of the enclosed International Search Report.				
	[] the enclosed English language abstracts.				
It is requested that the information disclosed herein be made of record in this application, and that the references listed on the enclosed form PTO/SB/08B appear under the "References Cited" heading of any Patent which issues from this application, (MPEP 1302.12).					
Statement Under 37 CFR 1.97(e):					
[]	Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or				
[]	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.				
Method of payment:					
[]	A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply.				
[X]	No fee is believed to be due for this submission, however, Applicant(s) hereby authorize the Commissioner to charge any fees that may be deemed to be due or to credit any overpayment to Deposit Account No. 50-0590. Two copies of this Statement are enclosed.				
[]	The Commissioner is hereby authorized to charge any deficiency in fees and credit any overpayment to Deposit Account <u>50-0590</u> . Two copies of this Statement are enclosed.				
	Respectfully submitted,				
Dated:_	BIOMEASURE, INCORPORATED By Alan F. Feeney, Attorney for Applicant(s) Registration No.: 43,609				
	Isure, Incorporated				

Biomeasure, Incorporated 27 Maple Street Milford, Massachusetts 01757 Phone: (508)478-0144 Facsimile: (508) 473-3531 JAN 3 0 2004

DOC	NO.

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO. 00537-181002

APPLICATION NO. 09/744,350

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

APPLICANT IGNATIOUS, Francis X.

FILING DATE 05/22/2001 EXAMINER/ART UNIT BORIN, M. / 1631

U.S. PATENT DOCUMENTS EXAM-FILING DATE SUB-INER DOCUMENT NUMBER DATE NAME CLASS CLASS ΙF INI-APPROPRIATE TIAL DA DB DC DΕ DF DG DH DI DJ DK FOREIGN PATENT DOCUMENTS SUB-TRANSLATION DOCUMENT NUMBER DATE COUNTRY CLASS CLASS YES DLWO 97/39738 10/30/1997 PCT WO 93/24150 12/09/1993 PCT DN DO DP DQ

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

HERMANN, J., et al. "Biodegradable, Somatostatin Acetate Containing DR Microspheres Prepared by Various Aqueous and Non-aqueous Solvent Evaporation Methods," European Journal of Pharmaceutics and Biopharmaceutics 45(1998):75-82.

EXAMINER

DATE CONSIDERED